vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $15.8M, roughly 1.2× Spire Global, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs -176.6%, a 242.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -26.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -32.6%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
SCYX vs SPIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $15.8M |
| Net Profit | $12.3M | $-28.0M |
| Gross Margin | — | 40.2% |
| Operating Margin | 56.3% | -164.1% |
| Net Margin | 65.7% | -176.6% |
| Revenue YoY | 1808.5% | -26.9% |
| Net Profit YoY | 376.5% | 42.7% |
| EPS (diluted) | $0.25 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $15.8M | ||
| Q3 25 | $334.0K | $12.7M | ||
| Q2 25 | $1.4M | $19.2M | ||
| Q1 25 | $257.0K | $23.9M | ||
| Q4 24 | $977.0K | $21.7M | ||
| Q3 24 | $660.0K | $28.6M | ||
| Q2 24 | $736.0K | $25.4M | ||
| Q1 24 | $1.4M | $34.8M |
| Q4 25 | $12.3M | $-28.0M | ||
| Q3 25 | $-8.6M | $-19.7M | ||
| Q2 25 | $-6.9M | $119.6M | ||
| Q1 25 | $-5.4M | $-20.7M | ||
| Q4 24 | — | $-48.8M | ||
| Q3 24 | $-2.8M | $-12.5M | ||
| Q2 24 | $-14.5M | $-16.6M | ||
| Q1 24 | $411.0K | $-25.5M |
| Q4 25 | — | 40.2% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 48.9% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | — | 44.5% | ||
| Q2 24 | — | 43.0% | ||
| Q1 24 | — | 26.5% |
| Q4 25 | 56.3% | -164.1% | ||
| Q3 25 | -2516.5% | -166.1% | ||
| Q2 25 | -701.0% | -122.7% | ||
| Q1 25 | -3350.2% | -106.5% | ||
| Q4 24 | — | -144.1% | ||
| Q3 24 | -1563.6% | -48.0% | ||
| Q2 24 | -1255.0% | -48.6% | ||
| Q1 24 | -692.5% | -34.4% |
| Q4 25 | 65.7% | -176.6% | ||
| Q3 25 | -2572.2% | -155.3% | ||
| Q2 25 | -504.8% | 623.4% | ||
| Q1 25 | -2097.7% | -86.5% | ||
| Q4 24 | — | -225.2% | ||
| Q3 24 | -425.5% | -43.7% | ||
| Q2 24 | -1964.4% | -65.2% | ||
| Q1 24 | 29.9% | -73.3% |
| Q4 25 | $0.25 | $-0.85 | ||
| Q3 25 | $-0.17 | $-0.61 | ||
| Q2 25 | $-0.14 | $3.72 | ||
| Q1 25 | $-0.11 | $-0.77 | ||
| Q4 24 | — | $-1.93 | ||
| Q3 24 | $-0.06 | $-0.50 | ||
| Q2 24 | $-0.30 | $-0.68 | ||
| Q1 24 | $0.01 | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $112.9M |
| Total Assets | $59.0M | $211.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $81.8M | ||
| Q3 25 | $37.9M | $96.8M | ||
| Q2 25 | $44.8M | $117.6M | ||
| Q1 25 | $40.6M | $35.9M | ||
| Q4 24 | $59.3M | $19.2M | ||
| Q3 24 | $68.8M | $36.6M | ||
| Q2 24 | $73.0M | $45.8M | ||
| Q1 24 | $80.2M | $63.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $123.1M |
| Q4 25 | $49.4M | $112.9M | ||
| Q3 25 | $36.4M | $133.1M | ||
| Q2 25 | $44.5M | $149.2M | ||
| Q1 25 | $50.5M | $3.7M | ||
| Q4 24 | $55.1M | $-11.7M | ||
| Q3 24 | $58.5M | $30.8M | ||
| Q2 24 | $60.4M | $40.3M | ||
| Q1 24 | $74.1M | $52.5M |
| Q4 25 | $59.0M | $211.0M | ||
| Q3 25 | $51.1M | $224.3M | ||
| Q2 25 | $60.7M | $239.5M | ||
| Q1 25 | $67.9M | $208.8M | ||
| Q4 24 | $90.6M | $193.6M | ||
| Q3 24 | $99.0M | $224.2M | ||
| Q2 24 | $107.8M | $230.8M | ||
| Q1 24 | $118.3M | $252.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 27.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-16.2M |
| FCF MarginFCF / Revenue | — | -102.1% |
| Capex IntensityCapex / Revenue | — | 75.1% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $-4.3M | ||
| Q3 25 | $-8.7M | $-12.0M | ||
| Q2 25 | $-7.5M | $-35.1M | ||
| Q1 25 | $-7.5M | $-8.4M | ||
| Q4 24 | $-24.0M | $-19.2M | ||
| Q3 24 | $765.0K | $14.0M | ||
| Q2 24 | $-10.9M | $-4.4M | ||
| Q1 24 | $-4.0M | $-8.8M |
| Q4 25 | — | $-16.2M | ||
| Q3 25 | — | $-20.4M | ||
| Q2 25 | — | $-38.7M | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | — | $-24.3M | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | — | $-9.9M | ||
| Q1 24 | — | $-15.9M |
| Q4 25 | — | -102.1% | ||
| Q3 25 | — | -161.3% | ||
| Q2 25 | — | -201.7% | ||
| Q1 25 | — | -72.6% | ||
| Q4 24 | — | -112.2% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | — | -39.0% | ||
| Q1 24 | — | -45.7% |
| Q4 25 | — | 75.1% | ||
| Q3 25 | — | 66.2% | ||
| Q2 25 | — | 18.8% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 31.2% | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | 20.3% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SPIR
Segment breakdown not available.
